A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of ALRN-5281 Administered by Subcutaneous Injection in Healthy Adult Volunteers
Latest Information Update: 17 Sep 2021
At a glance
- Drugs ALRN 5281 (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Aileron Therapeutics
- 04 Dec 2013 New trial record